Critical review of BPC-157 in rodent ischemia-reperfusion injury reports heterogeneous preclinical evidence

This is a critical review of preclinical animal evidence, drawing on peer-reviewed rodent studies rather than on people; no participant or animal total is reported for the review as a whole, so the sample size is unknown. The authors state they searched up to 24 June 2026 across PubMed/MEDLINE, Web of Science Core Collection, Scopus, PMC, publisher and DOI metadata, ClinicalTrials.gov, FDA materials, and WADA materials.

According to the abstract, rodent studies using conventional organ-specific ischemia-reperfusion injury or reperfusion-associated systemic injury were treated as the core evidence and evaluated by experimental model, BPC 157 dose, route and timing, measured outcomes, and methodological limitations. Selected major-vessel occlusion models were considered separately as related in vivo vascular evidence.

Across the rodent literature surveyed, the authors report that BPC 157 administration has been associated with attenuation of oxidative injury, modulation of nitric oxide-related vascular responses, reductions in inflammatory and apoptotic markers, and changes in VEGF/VEGFR2-Akt-eNOS-related signaling. These are animal findings and the review does not present them as evidence in humans.

Organ-specific observations listed in the abstract include biochemical, molecular and histological protection in lower-extremity skeletal-muscle injury, attenuation of distant-organ injury following limb injury, neuronal and functional effects in hippocampal injury, vascular and tissue-protective responses in intestinal and colonic injury, and hemodynamic and histological effects in hepatic Pringle-maneuver injury.

The authors write that current evidence supports BPC 157 as a hypothesis-generating investigational candidate for further preclinical research rather than as an established therapy, and that independent blinded replication, dose-response and therapeutic-window work, pharmacokinetic and pharmacodynamic characterization, rigorous toxicology and controlled human studies would be required before clinical translation could be considered.

The authors state that meta-analysis was not performed because of substantial heterogeneity in organ systems, injury paradigms, doses, routes, treatment timing, and outcome measures, so no pooled effect estimate exists. They also describe the evidence base as heterogeneous and as frequently relying on short observation periods, single-dose paradigms, and incompletely characterized risk-of-bias domains.

The abstract notes that endothelial, vascular-ring, human ex vivo, and regulatory or clinical sources were used as contextual evidence rather than as evidence of efficacy in ischemia-reperfusion injury, and that reperfusion-like systemic and major-vessel occlusion models should not be considered equivalent to conventional organ-specific models. As a narrative review of rodent work, it carries the structural limits of secondary synthesis: no new data, selection decisions made by the authors, and findings confined to animals.

The abstract does not report individual study doses, routes or schedules, so no regimen can be summarized here.

BPC-157, also written BPC 157 or pentadecapeptide BPC 157, is not an FDA-approved drug for any use. This status comes from the site's regulatory review and not from this review article.